On September 19, the Lasker Prize, an important award in the biomedical field known as the "vane" of the Nobel Prize, was announced.

Among them, Joel Habener of Massachusetts General Hospital, Svetlana Mojsov of Rockefeller University, Lotte Bjerre Knudsen of Novo Nordisk won the Lasker Award for Clinical Medical Research.

Chen Zhijian, a Chinese scientist from the University of Texas Southwestern Medical Center, won the Lasker Award for Basic Medical Research. Quarraisha Abdool Karim and Salim S. Abdool Karim of the South African Centre for AIDS Research/Columbia University, USA, received the Lasker Award for Public Service.

According to Science, three winners of the Lasker Award for Clinical Medical Research have discovered and developed GLP-1 (glucagon-like peptide-1) drugs.

Habener and Mojsov's research identified the active form of GLP-1, and Knudsen translated this discovery into an effective weight-loss drug that could be used in the clinic.

The drug has significantly changed the landscape of obesity treatment, providing a new solution for millions of patients worldwide.

The citation reads: "Nearly 900 million adults worldwide are obese, and excess weight leads to multiple life-threatening conditions.

Obesity is often thought of as a failure of willpower, but for many people, diet and exercise don't solve the problem. Historically, attempts to create safe and effective drugs to help people lose weight have failed.

And with the three of them working together, we've entered a new era of weight management, where GLP-1-based drugs hold the promise of dramatically improving health."

However, one of the recipients was unknown until a year ago: Mojsov. After winning the prize, the chemist had a second thought about how honors in science should be distributed.

In the 1980s, Mojsov, who worked at Massachusetts General Hospital, published important papers on GLP-1. It was because of her discovery that GLP-1 receptor agonist drugs became a reality.

However, Mojsov's efforts, as an important figure in this research, have been ignored. She had to go through a protracted legal battle to get her name added to the underlying patent as a co-inventor.

It wasn't until last September, some 40 years after Mojsov began working on GLP-1, that her name became more widely known when media outlets like Science reported on her story.

"I'm excited to rejoin the story because I was there in the first place." "I think the whole thing is no longer about me," Mojsov told reporters. "It's about scientific credibility."

Mojsov said: "There is an outdated view that senior scientists contribute to knowledge, while young scientists only help.

But science is a collaboration, and young scientists, junior researchers, should also get the credit they deserve. I hope my case will help people understand this."

As for the future direction of GLP-1 research, Mojsov said, first of all, to really understand how GLP-1 works in the brain, how it regulates obesity and all other diseases. Second, consider how to develop better chemicals to make GLP-1 drugs more effective and cheaper, something many companies are working on.